Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00057642
Status:
COMPLETED
Last Update Posted:
2013-08-20
First Post:
2003-04-04
Brief Title:
Improving Retention of Hispanics Receiving Antidepressant Therapy
Sponsor:
New York State Psychiatric Institute
Organization:
New York State Psychiatric Institute
Study Overview
Official Title:
Improving Hispanic Retention in Antidepressant Therapy
Status:
COMPLETED
Status Verified Date:
2008-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will develop an intervention that will increase the retention of Hispanics with major depression in antidepressant therapy
Detailed Description:
Despite major advances in the treatment of psychiatric disorders Hispanics continue to underutilize mental health services relative to their own mental health needs Cultural factors are important causes of underutilization To date however attempts to boost utilization by improving the cultural congruence of psychiatric services have not focused on retaining Hispanics in antidepressant therapy
Motivational Interviewing MI is a time-limited psychotherapy that has successfully improved treatment retention among patients with dually diagnosed substance abuse and psychiatric disorders During Phase I of this study MI is adapted for use as an adjunctive therapy with antidepressant treatment and culturally adapted to Hispanic participants In Phase II participants receive sertraline for 12 weeks and participate in four sessions of MI therapy as a supplementary intervention designed to encourage treatment retention Participants who are intolerant to sertraline or have an inadequate response by Week 6 are switched to venlafaxine ER while continuing to receive MI and to complete study assessments A follow-up interview is conducted 6 months after the termination of treatment
Motivational Interviewing MI is a time-limited psychotherapy that has successfully improved treatment retention among patients with dually diagnosed substance abuse and psychiatric disorders During Phase I of this study MI is adapted for use as an adjunctive therapy with antidepressant treatment and culturally adapted to Hispanic participants In Phase II participants receive sertraline for 12 weeks and participate in four sessions of MI therapy as a supplementary intervention designed to encourage treatment retention Participants who are intolerant to sertraline or have an inadequate response by Week 6 are switched to venlafaxine ER while continuing to receive MI and to complete study assessments A follow-up interview is conducted 6 months after the termination of treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DSIR SE-SC | US NIH GrantContract | None | httpsreporternihgovquickSearchR21MH066388 |
| R21MH066388 | NIH | None | None |